[144] Ocular Therapeutix, Inc. SEC Filing

Rhea-AI Filing Summary

Ocular Therapeutix, Inc. (OCUL) filed a Form 144 reporting a proposed sale of 3,011 shares of common stock with an aggregate market value of $36,252.74. The shares represent a very small portion of the company’s reported 173,995,221 outstanding shares and are listed for sale on NASDAQ with an approximate sale date of 08/25/2025.

The filing notes the shares were acquired on 08/22/2025 from restricted stock vesting under a registered plan and that no securities of the issuer were sold by the reporting person in the past three months. The filer certifies there is no undisclosed material adverse information about the issuer in connection with this notice.

Positive

• Transparent disclosure of a proposed insider sale under Rule 144 with broker and sale-date details
• Shares originated from restricted stock vesting under a registered plan, indicating routine compensation liquidity
• No sales in past three months reported for the selling person, reducing signals of accelerated insider selling

Negative

• None.

Insights

Securities Analyst

TL;DR Routine insider sale notice for a small number of vested shares; immaterial to market cap.

The Form 144 discloses a proposed sale of 3,011 vested shares valued at $36,252.74, representing approximately 0.0017% of the stated outstanding shares (3,011 of 173,995,221). This appears to be a routine liquidity event from restricted stock vesting rather than a large insider divestiture. The filing includes the standard certification that no material nonpublic information is known to the seller. Given the size relative to outstanding shares, the immediate market impact is likely negligible.

Corporate Governance Expert

TL;DR Proper Rule 144 disclosure of vested shares; procedural compliance reduces governance risk.

The document shows compliance with Rule 144 timing and reporting requirements: acquisition date, nature of acquisition (restricted stock vesting under a registered plan), broker details, and planned sale date. The absence of prior sales in the past three months and the signer’s representation about undisclosed material information are standard controls that support transparent insider trading practices. No governance red flags are evident from the content provided.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	3011	36252.74	173995221	08/25/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/22/2025	Restricted stock vesting under a registered plan	Issuer			3011	08/22/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Ocular Therapeutix's Form 144 say about the number of shares being sold?

The filing reports a proposed sale of 3,011 shares of common stock.

What is the aggregate market value and planned sale date on OCUL's Form 144?

Aggregate market value is listed as $36,252.74 with an approximate sale date of 08/25/2025.

How were the shares acquired that are being sold under this Form 144 for OCUL?

The shares were acquired on 08/22/2025 via restricted stock vesting under a registered plan.

On which exchange is the proposed sale of OCUL shares to occur?

The filing lists NASDAQ as the securities exchange for the proposed sale.

Does the filer report any securities sold during the past three months?

The filing states Nothing to Report for securities sold during the past three months by the reporting person.